Logo

Drug Discovery & Development

News on drug screening, clinical trials, companion diagnostics, immunotherapy, & personalized therapies in genetics, genomics, and molecular diagnostics.

Sep 23, 2022

Galecto Explores Anti-Cancer Potential of Inhibiting Fibrosis, Scarring Pathway
Premium

Sep 22, 2022

Revolution Medicines Begins Phase I Trial of KRAS G12C Inhibitor

Sep 21, 2022

Immunitas Cleared by FDA to Begin Trial of IMT-009 in Hematologic Malignancies, Solid Tumors

Sep 21, 2022

Merck KGaA, Nerviano Enter License Agreement for PARP1 Inhibitor NMS-293

Sep 21, 2022

Abpro Licenses HER2-Targeteing Bispecific Antibody to Celltrion

Sep 20, 2022

Elicio Receives $2.8M Grant for Cancer Vaccine Development

Sep 20, 2022

Gradalis' Autologous Immunotherapy Shows Promise in Certain Ovarian Cancer Patients
Premium

Sep 20, 2022

Verismo Therapeutics to Begin Phase I Trial of Autologous Cell Therapy SynKIR-110

Sep 20, 2022

ImmunoScape Raises $14M

Sep 16, 2022

Biocytogen Pharmaceuticals, Guangzhou FineImmune Biotechnology Ink Cell Therapy Partnership

Sep 15, 2022

BriaCell, Caris Life Sciences Partner to Bolster New Immunotherapy Development

Sep 14, 2022

FDA Clears Anbogen Therapeutics to Study ABT-101 in HER2-Mutant NSCLC Patients in the US

Sep 13, 2022

Combination Trials Point to New Potential Treatment Strategies in Breast Cancer
Premium

Sep 13, 2022

Cardiff Oncology Launches Phase II Trial of PLK1 Inhibitor in RAS-Mutated Colon Cancer

Sep 13, 2022

Relay Therapeutics' Selective FGFR2 Inhibitor Yields 'Remarkable' Responses in Bile Duct Cancer
Premium

Sep 13, 2022

METiS Gets Exclusive License to Voronoi's Pan-RAF Inhibitor

Sep 13, 2022

ESMO Data Deepens Understanding of KRAS Inhibitor Activity in Lung, Colorectal Cancer
Premium

Sep 11, 2022

TIL Therapy Bests Yervoy in Head-to-Head Melanoma Trial; Will It Reach Patients Without Pharma?
Premium

Sep 10, 2022

BMS Combo Drug Opdualag Effective in Neoadjuvant NSCLC, But Maybe No Better Than Opdivo Alone
Premium

Sep 9, 2022

Virogin Biotech, MD Anderson Ink Collaboration to Study Oncolytic Viruses